Under physiological conditions the rate limiting enzyme in the generation of angiotensin II is: A. Renin B. Angiotensin converting enzyme C. Aminopeptidase D. Angiotensinase

Under physiological conditions the rate limiting enzyme
in the generation of angiotensin II is:
A. Renin
B. Angiotensin converting enzyme
C. Aminopeptidase
D. Angiotensinase
by

1 Answer

Answer :

A. Renin
by

Related questions

Angiotensin converting enzyme inhibitors are contraindicated in: A. High renin hypertensives B. Diabetics C. Congestive heart failure patients D. Pregnant women

Description : Angiotensin converting enzyme inhibitors are contraindicated in: A. High renin hypertensives B. Diabetics C. Congestive heart failure patients D. Pregnant women

Last Answer : D. Pregnant women

Angiotensin converting enzyme inhibitors reduce the following haemodynamic parameters in congestive heart failure except: A. Systemic vascular resistance B. Right atrial pressure C. Cardiac output D. Heart rate × pressure product

Description : Angiotensin converting enzyme inhibitors reduce the following haemodynamic parameters in congestive heart failure except: A. Systemic vascular resistance B. Right atrial pressure C. Cardiac output D. Heart rate × pressure product

Last Answer : C. Cardiac output

The following type of vasodilator is not beneficial in CHF due to systolic dysfunction: A. Calcium channel blocker B. Angiotensin converting enzyme inhibitor C. Nitrate D. Hydralazine

Description : The following type of vasodilator is not beneficial in CHF due to systolic dysfunction: A. Calcium channel blocker B. Angiotensin converting enzyme inhibitor C. Nitrate D. Hydralazine

Last Answer : A. Calcium channel blocker

Clinically, the angiotensin antagonists share the following features of angiotensin converting enzyme inhibitors except: A. Antihypertensive efficacy B. Potential to reverse left ventricular hypertrophy C. Lack of effect on carbohydrate tolerance D. Potential to induce cough in susceptible individuals

Description : Clinically, the angiotensin antagonists share the following features of angiotensin converting enzyme inhibitors except: A. Antihypertensive efficacy B. Potential to reverse left ventricular hypertrophy ... of effect on carbohydrate tolerance D. Potential to induce cough in susceptible individuals

Last Answer : D. Potential to induce cough in susceptible individuals

Angiotensin converting enzyme inhibitors afford maximum protection against progression of heart failure when used: A. At the higher therapeutic dose range over long term B. At the maximum tolerated dose only till haemodynamic compensation is restored C. At low doses over long term D. At low doses along with diuretics/digoxi

Description : Angiotensin converting enzyme inhibitors afford maximum protection against progression of heart failure when used: A. At the higher therapeutic dose range over long term B. At the maximum tolerated dose only till ... restored C. At low doses over long term D. At low doses along with diuretics/digoxi

Last Answer : A. At the higher therapeutic dose range over long term

Advantages of angiotensin converting enzyme inhibitors as antihypertensive include the following except: A. They tend to reverse left ventricular hypertrophy B. Their efficacy is not reduced by nonsteroidal antiinflammatory drugs C. They do not worsen blood lipid profile D. They do not impair work performance

Description : Advantages of angiotensin converting enzyme inhibitors as antihypertensive include the following except: A. They tend to reverse left ventricular hypertrophy B. Their efficacy is not reduced by nonsteroidal ... . They do not worsen blood lipid profile D. They do not impair work performance

Last Answer : B. Their efficacy is not reduced by nonsteroidal antiinflammatory drugs

Potentiation of bradykinin appears to play a role in the following effects of angiotensin converting enzyme inhibitors except: A. Fall in BP in the short term B. Fall in BP in the long term C. Cough in susceptible individuals D. Angioedema in susceptible individuals

Description : Potentiation of bradykinin appears to play a role in the following effects of angiotensin converting enzyme inhibitors except: A. Fall in BP in the short term B. Fall in BP in the long term C. Cough in susceptible individuals D. Angioedema in susceptible individuals

Last Answer : B. Fall in BP in the long term

Which of the following statements about hypertension in diabetes patients is/are correct? A. Hypertension worsens the macrovascular disease of diabetes patients. B. Hypertension accelerates the progression of diabetic nephropathy. C. Hypertension is associated with sodium retention in diabetes patients. D. Angiotensin-converting enzyme (ACE) inhibitors should be used in all patients with chronic hyperglycemia, regardless of the presence of hypertension. E. Diuretics, as single-drug therapy, are not indicated in the treatment of hypertension in diabetes patients.

Description : Which of the following statements about hypertension in diabetes patients is/are correct? A. Hypertension worsens the macrovascular disease of diabetes patients. B. Hypertension accelerates the ... single-drug therapy, are not indicated in the treatment of hypertension in diabetes patients.

Last Answer : Answer: ABCDE DISCUSSION: All of the answers listed are correct. By damaging endothelial cells, hypertension worsens macrovascular disease in all patients but especially in diabetics. Hypertension ... is not indicated because the chronic state of dehydration in such patients may become worse

Sildenafil is contraindicated in patients taking the following class of drugs: A. α-adrenergic blockers B. β-adrenergic blockers C. Organic nitrates D. Angiotensin converting enzyme inhibitors

Description : Sildenafil is contraindicated in patients taking the following class of drugs: A. α-adrenergic blockers B. β-adrenergic blockers C. Organic nitrates D. Angiotensin converting enzyme inhibitors

Last Answer : C. Organic nitrates

Sildenafil is contraindicated in patients taking the following class of drugs: A. α-adrenergic blockers B. β-adrenergic blockers C. Organic nitrates D. Angiotensin converting enzyme inhibitors

Description : Sildenafil is contraindicated in patients taking the following class of drugs: A. α-adrenergic blockers B. β-adrenergic blockers C. Organic nitrates D. Angiotensin converting enzyme inhibitors

Last Answer : C. Organic nitrates

Aldosterone release is stimulated by (A) α2-Globulin (B) Renin (C) Angiotensin II (D) Growth hormone

Description : Aldosterone release is stimulated by (A) α2-Globulin (B) Renin (C) Angiotensin II (D) Growth hormone

Last Answer : Answer : C

Actions of angiotensin II include: a. increases the release of aldosterone b. reduces renin release from the kidney c. vasodilatation d. promotes microalbuminuria

Description : Actions of angiotensin II include: a. increases the release of aldosterone b. reduces renin release from the kidney c. vasodilatation d. promotes microalbuminuria

Last Answer : promotes microalbuminuria

Fight-or-flight reactions cause activation of (a) the parathyroid glands, leading to increased metabolic rate (b) the kidney, leading to suppression of renin- angiotensin-aldosterone pathway (c) the adrenal medulla, leading to increased secretion of epinephrine and norepinephrine (d) the pancreas leading to a reduction in the blood sugar levels.

Description : Fight-or-flight reactions cause activation of (a) the parathyroid glands, leading to increased metabolic rate (b) the kidney, leading to suppression of renin- angiotensin-aldosterone pathway (c) ... epinephrine and norepinephrine (d) the pancreas leading to a reduction in the blood sugar levels.

Last Answer : (c) the adrenal medulla, leading to increased secretion of epinephrine and norepinephrine

Which of the following statements most closely describes the current status of angiotensin converting enzyme inhibitors in congestive heart failure: A. They are the first choice drugs unless contraindicated B. They are used when diuretics alone fail C. They are a substitute for digitalis D. They are to be used as adjuncts only in resistant cases

Description : Which of the following statements most closely describes the current status of angiotensin converting enzyme inhibitors in congestive heart failure: A. They are the first choice drugs unless contraindicated B. ... substitute for digitalis D. They are to be used as adjuncts only in resistant cases

Last Answer : D. They are to be used as adjuncts only in resistant cases

What is the function of Renin-Angiotensin in the regulation of kidney function? -Biology

Description : What is the function of Renin-Angiotensin in the regulation of kidney function? -Biology

Last Answer : answer:

Assertion `:-` Feedback mechanism for regulartion of kidney involve hypothalamus & JGA. Reason `:-` ANF mechanism check renin-angiotensin mechanism.

Description : Assertion `:-` Feedback mechanism for regulartion of kidney involve hypothalamus & JGA. Reason `:-` ANF mechanism check renin-angiotensin mechanism.

Last Answer : Assertion `:-` Feedback mechanism for regulartion of kidney involve hypothalamus & JGA. Reason `:-` ANF ... D. If both Assertion & Reason are false.

Assertion `:-` An increase in glomerular blood pressure can activate the JG of kidney to release renin. Reason `:-` Angiotensin I is a powerful vaso c

Description : Assertion `:-` An increase in glomerular blood pressure can activate the JG of kidney to release renin. Reason `:-` Angiotensin I is a powerful vaso c

Last Answer : Assertion `:-` An increase in glomerular blood pressure can activate the JG of kidney to release renin. ... . D. If both Assertion & Reason are false.

Methyl dopa decreases blood pressure by (A) Inhibiting the synthesis of catecholamines (B) Antagonising the action of aldosterone (C) Stimulating the release of renin (D) Inhibiting the breakdown of angiotensin

Description : Methyl dopa decreases blood pressure by (A) Inhibiting the synthesis of catecholamines (B) Antagonising the action of aldosterone (C) Stimulating the release of renin (D) Inhibiting the breakdown of angiotensin

Last Answer : Answer : A

Which of the following statement(s) is/are true concerning the neuroendocrine responses to shock? a. Sympathetic nerve endings release epinephrine which is responsible for greater than 80% of systemic vascular resistance b. Endogenous epinephrine is the primary contributor to systemic vascular resistance c. Increased pancreatic secretion of glucagon contributes to glucose intolerance associated with injury and sepsis d. The renin-angiotensin axis further augments the sympathetic-mediated vasoconstriction

Description : Which of the following statement(s) is/are true concerning the neuroendocrine responses to shock? a. Sympathetic nerve endings release epinephrine which is responsible for greater than 80% ... injury and sepsis d. The renin-angiotensin axis further augments the sympathetic-mediated vasoconstriction

Last Answer : Answer: c, d The neuroendocrine response to shock attempts to achieve restoration of effective blood volume, mobilization of metabolic substrates, and maintenance of central ... . Angiotensin II is an extremely effective vasoconstrictor that further augments sympathetic-mediated vasoconstriction

Select the nonapeptide which can be generated from plasma globulin by snake venom enzymes, causes fall in BP and intense pain when applied to blister base: A. Kallidin B. Bradykinin C. Angiotensin II D. Angiotensin III

Description : Select the nonapeptide which can be generated from plasma globulin by snake venom enzymes, causes fall in BP and intense pain when applied to blister base: A. Kallidin B. Bradykinin C. Angiotensin II D. Angiotensin III

Last Answer : B. Bradykinin

Bradykinin and angiotensin II have the following feature common to both: A. They both cause fall in BP B. They both are degraded by Kininase II C. Their precursor proteins are plasma α2 globulins D. They both release aldosterone from adrenal cortex

Description : Bradykinin and angiotensin II have the following feature common to both: A. They both cause fall in BP B. They both are degraded by Kininase II C. Their precursor proteins are plasma α2 globulins D. They both release aldosterone from adrenal cortex

Last Answer : C. Their precursor proteins are plasma α2 globulins

Enalapril differs from captopril in that: A. It blocks angiotensin II receptors B. It does not produce cough as a side effect C. It is less liable to cause abrupt first dose hypotension D. It has a shorter duration of action

Description : Enalapril differs from captopril in that: A. It blocks angiotensin II receptors B. It does not produce cough as a side effect C. It is less liable to cause abrupt first dose hypotension D. It has a shorter duration of action

Last Answer : C. It is less liable to cause abrupt first dose hypotension

Captopril pretreatment: A. Inhibits the pressor action of angiotensin I B. Inhibits the pressor action of angiotensin II C. Potentiates the depressor action of bradykinin D. Both ‘A’ and ‘C’ are correct

Description : Captopril pretreatment: A. Inhibits the pressor action of angiotensin I B. Inhibits the pressor action of angiotensin II C. Potentiates the depressor action of bradykinin D. Both ‘A’ and ‘C’ are correct

Last Answer : D. Both ‘A’ and ‘C’ are correct

Ventricular remodeling after myocardial infarction involves the mediation of: A. Angiotensin II B. Prostaglandin C. Bradykinin D. Thromboxane A2

Description : Ventricular remodeling after myocardial infarction involves the mediation of: A. Angiotensin II B. Prostaglandin C. Bradykinin D. Thromboxane A2

Last Answer : A. Angiotensin II

Angiotensin II plays a key role in the following risk factor for ischaemic heart disease: A. Hypercholesterolemia B. Ventricular hypertrophy C. Carbohydrate intolerance D. Cardiac arrhythmia

Description : Angiotensin II plays a key role in the following risk factor for ischaemic heart disease: A. Hypercholesterolemia B. Ventricular hypertrophy C. Carbohydrate intolerance D. Cardiac arrhythmia

Last Answer : B. Ventricular hypertrophy

Angiotensin III is equipotent to angiotensin II in: A. Releasing aldosterone from adrenal cortex B. Promoting Na+ and water reabsorption by direct intrarenal action C. Causing vasoconstriction D. Contracting intestinal smooth muscle

Description : Angiotensin III is equipotent to angiotensin II in: A. Releasing aldosterone from adrenal cortex B. Promoting Na+ and water reabsorption by direct intrarenal action C. Causing vasoconstriction D. Contracting intestinal smooth muscle

Last Answer : A. Releasing aldosterone from adrenal cortex

Angiotensin II causes rise in blood pressure by: A. Direct vasoconstriction B. Releasing adrenaline from adrenal medulla C. Increasing central sympathetic tone D. All of the above

Description : Angiotensin II causes rise in blood pressure by: A. Direct vasoconstriction B. Releasing adrenaline from adrenal medulla C. Increasing central sympathetic tone D. All of the above

Last Answer : D. All of the above

There are no preformed stores of the following autacoid/autacoids: A. Prostaglandins B. Leukotrienes C. Angiotensin II D. All of the above

Description : There are no preformed stores of the following autacoid/autacoids: A. Prostaglandins B. Leukotrienes C. Angiotensin II D. All of the above

Last Answer : D. All of the above

Which of the following is known as bone forming enzyme? (A) Alkaline phosphatase (B) Acid phosphatase (C) Leucine aminopeptidase (D) γ-glutamyl transpeptidase

Description : Which of the following is known as bone forming enzyme? (A) Alkaline phosphatase (B) Acid phosphatase (C) Leucine aminopeptidase (D) γ-glutamyl transpeptidase

Last Answer : Answer : A

Which of the following is a substratespecific enzyme? (A) Hexokinase (B) Thiokinase (C) Lactase (D) Aminopeptidase

Description : Which of the following is a substratespecific enzyme? (A) Hexokinase (B) Thiokinase (C) Lactase (D) Aminopeptidase

Last Answer : Answer : C

Choose the correct statement about lovastatin: A. It markedly lowers plasma triglyceride with little effect on cholesterol level B. It is used as an adjuvant to gemfibrozil for type III hyperlipoproteinemia C. It is not effective in diabetes associated hypercholesterolemia D. It is a competitive inhibitor of the rate limiting step in cholesterol synthesis

Description : Choose the correct statement about lovastatin: A. It markedly lowers plasma triglyceride with little effect on cholesterol level B. It is used as an adjuvant to gemfibrozil for type III ... hypercholesterolemia D. It is a competitive inhibitor of the rate limiting step in cholesterol synthesis

Last Answer : D. It is a competitive inhibitor of the rate limiting step in cholesterol synthesis

The following antihypertensive drug tends to lower plasma renin activity: A. Clonidine B. Hydralazine C. Nifedipine D. Captopril

Description : The following antihypertensive drug tends to lower plasma renin activity: A. Clonidine B. Hydralazine C. Nifedipine D. Captopril

Last Answer : A. Clonidine

Methyldopa differs from clonidine in the following respect: A. It is less likely to cause rebound hypertension on sudden discontinuation B. It does not reduce plasma renin activity C. It has a central as well as peripheral site of antihypertensive action D. It does not produce central side effect

Description : Methyldopa differs from clonidine in the following respect: A. It is less likely to cause rebound hypertension on sudden discontinuation B. It does not reduce plasma renin activity C. It has a central as well as peripheral site of antihypertensive action D. It does not produce central side effect

Last Answer : A. It is less likely to cause rebound hypertension on sudden discontinuation

Captopril produces greater fall in blood pressure in: A. Diuretic treated patients B. Patients having low plasma renin activity C. Sodium replete normotensive individuals D. Untreated CHF patient

Description : Captopril produces greater fall in blood pressure in: A. Diuretic treated patients B. Patients having low plasma renin activity C. Sodium replete normotensive individuals D. Untreated CHF patient

Last Answer : A. Diuretic treated patients

The following factors enhance renin release from the kidney except: A. Fall in blood pressure B. Reduction in blood volume C. Enhanced sympathetic activity D. Volume overload

Description : The following factors enhance renin release from the kidney except: A. Fall in blood pressure B. Reduction in blood volume C. Enhanced sympathetic activity D. Volume overload

Last Answer : D. Volume overload

All of the following contribute to the antihypertensive action of propranolol except: A. Direct vasodilatation B. Decreased renin release from kidney C. Adaptation of blood vessels to reduced cardiac output D. Less noradrenaline release from sympathetic nerve endings

Description : All of the following contribute to the antihypertensive action of propranolol except: A. Direct vasodilatation B. Decreased renin release from kidney C. Adaptation of blood vessels to reduced cardiac output D. Less noradrenaline release from sympathetic nerve endings

Last Answer : A. Direct vasodilatation

All of the following contribute to the antihypertensive action of propranolol except: A. Direct vasodilatation B. Decreased renin release from kidney C. Adaptation of blood vessels to reduced cardiac output D. Less noradrenaline release from sympathetic nerve endings

Description : All of the following contribute to the antihypertensive action of propranolol except: A. Direct vasodilatation B. Decreased renin release from kidney C. Adaptation of blood vessels to reduced cardiac output D. Less noradrenaline release from sympathetic nerve endings

Last Answer : A. Direct vasodilatation

Choose the drug that selectively blocks AT1 subtype of angiotensin receptors: A. Ramipril B. Lovastatin C. Candesartan D. Sumatriptan

Description : Choose the drug that selectively blocks AT1 subtype of angiotensin receptors: A. Ramipril B. Lovastatin C. Candesartan D. Sumatriptan

Last Answer : C. Candesartan

The following is a pressor peptide that can be generated both in circulation as well as locally in certain tissues: A. Bradykinin B. Angiotensin C. Kallidin D. Plasmin

Description : The following is a pressor peptide that can be generated both in circulation as well as locally in certain tissues: A. Bradykinin B. Angiotensin C. Kallidin D. Plasmin

Last Answer : B. Angiotensin

Select the receptor that is located intracellularly: A. Opioid μ receptor B. Steroid receptor C. Prostaglandin receptor D. Angiotensin receptor

Description : Select the receptor that is located intracellularly: A. Opioid μ receptor B. Steroid receptor C. Prostaglandin receptor D. Angiotensin receptor

Last Answer : B. Steroid receptor

The dose of the following class of drugs has to be adjusted by repeated measurement of the affected physiological parameter: A. Oral contraceptives B. Antiepileptics C. Antidepressants D. Oral anticoagulants

Description : The dose of the following class of drugs has to be adjusted by repeated measurement of the affected physiological parameter: A. Oral contraceptives B. Antiepileptics C. Antidepressants D. Oral anticoagulants

Last Answer : D. Oral anticoagulants

For Catecholamine biosynthesis the rate limiting enzyme is (A) DOPA decarboxylase (B) DOPAMINE β-hydroxylase (C) Tyrosine hydroxylase (D) Phenylalanine hydroxylase

Description : For Catecholamine biosynthesis the rate limiting enzyme is (A) DOPA decarboxylase (B) DOPAMINE β-hydroxylase (C) Tyrosine hydroxylase (D) Phenylalanine hydroxylase

Last Answer : Answer : C

In the biosynthesis of cholesterol, the rate limiting enzyme is (A) Mevalonate kinase (B) HMG-CoA synthetase (C) HMG-CoA reductase (D) Cis-prenyl transferase

Description : In the biosynthesis of cholesterol, the rate limiting enzyme is (A) Mevalonate kinase (B) HMG-CoA synthetase (C) HMG-CoA reductase (D) Cis-prenyl transferase

Last Answer : Answer : C

If all the enzymes, intermediates and cofactors of the citric acid cycle as well as an excess of the starting substrate acetylCoA are present and functional in an organelle free solution at the appropriate pH, which of the following factors of the citric acid cycle would prove to be rate limiting? (A) Molecular oxygen (B) Half life of enzyme (C) Turnover of intermediates (D) Reduction of cofactors

Description : If all the enzymes, intermediates and cofactors of the citric acid cycle as well as an excess of the starting substrate acetylCoA are present and functional in an organelle free solution at the appropriate ... oxygen (B) Half life of enzyme (C) Turnover of intermediates (D) Reduction of cofactors

Last Answer : Answer : D

Which one of the following is a rate limiting enzyme of gluconeogenesis? (A) Hexokinase (B) Phsophofructokinase (C) Pyruvate carboxylase (D) Pyruvate kinase

Description : Which one of the following is a rate limiting enzyme of gluconeogenesis? (A) Hexokinase (B) Phsophofructokinase (C) Pyruvate carboxylase (D) Pyruvate kinase

Last Answer : C

What is the rate limiting enzyme of de novo synthesis of fatty acid?

Description : What is the rate limiting enzyme of de novo synthesis of fatty acid?

Last Answer : Acetyl CoA carboxylase.

In the lens: a. the capsule is made up of type IV collagen b. most metabolism is carried out in the anterior pole c. hexokinase is a rate-limiting enzyme in carbohydrate metabolism d. all above

Description : In the lens: a. the capsule is made up of type IV collagen b. most metabolism is carried out in the anterior pole c. hexokinase is a rate-limiting enzyme in carbohydrate metabolism d. all above

Last Answer : all above

The rate limiting step in cholesterol biosynthesis is one of the followings : (A) LDL-receptor concentration (B) VLDL secretion (C) Mevalonic acid formation (D) Co-enzyme A formation

Description : The rate limiting step in cholesterol biosynthesis is one of the followings : (A) LDL-receptor concentration (B) VLDL secretion (C) Mevalonic acid formation (D) Co-enzyme A formation

Last Answer : (C) Mevalonic acid formation

The rate limiting enzyme in the synthesis of catecholamines is: A. Tyrosine hydroxylase B. Dopa decarboxylase C. Dopamine β-hydroxylase D. Noradrenaline N-methyl transferase

Description : The rate limiting enzyme in the synthesis of catecholamines is: A. Tyrosine hydroxylase B. Dopa decarboxylase C. Dopamine β-hydroxylase D. Noradrenaline N-methyl transferase

Last Answer : A. Tyrosine hydroxylase

The rate limiting enzyme in the synthesis of catecholamines is: A. Tyrosine hydroxylase B. Dopa decarboxylase C. Dopamine β-hydroxylase D. Noradrenaline N-methyl transferase

Description : The rate limiting enzyme in the synthesis of catecholamines is: A. Tyrosine hydroxylase B. Dopa decarboxylase C. Dopamine β-hydroxylase D. Noradrenaline N-methyl transferase

Last Answer : A. Tyrosine hydroxylase